Jiangsu Gdk Biological Technology Co., Ltd (SHA:688670)
China · Delayed Price · Currency is CNY 21.07
+0.51 (2.48%)
At close: Jan 23, 2026
SHA:688670 Revenue
Jiangsu Gdk Biological Technology had revenue of 71.13M CNY in the quarter ending September 30, 2025, with 99.75% growth. This brings the company's revenue in the last twelve months to 116.56M, up 121.40% year-over-year. In the year 2024, Jiangsu Gdk Biological Technology had annual revenue of 80.80M, down -39.96%.
Revenue (ttm)
116.56M
Revenue Growth
+121.40%
P/S Ratio
22.27
Revenue / Employee
257.88K
Employees
449
Market Cap
2.60B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 80.80M | -53.79M | -39.96% |
| Dec 31, 2023 | 134.59M | -183.89M | -57.74% |
| Dec 31, 2022 | 318.49M | -73.79M | -18.81% |
| Dec 31, 2021 | 392.27M | -196.83M | -33.41% |
| Dec 31, 2020 | 589.10M | 521.95M | 777.27% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Shanghai Universal Biotech | 1.07B |
| Shandong Sito Bio-technology | 954.76M |
| Zhejiang East Asia Pharmaceutical | 831.56M |
| Guiyang Xintian Pharmaceutical | 755.34M |
| Jilin Jian Yisheng Pharmaceutical | 639.10M |
| Hubei Goto Biopharm | 626.28M |
| Jiangsu Sihuan Bioengineering | 341.90M |
| Sailong Pharmaceutical Group | 244.84M |